Dihydroergotamine nasal spray for relief of refractory headache: A retrospective chart review

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 751-755

  Fisher, Michele ^a   Gosy, Eugene J ^a   Heary, Blanka ^a   Shaw, Denise ^a  

^a Gosy and Associates Pain Treatment and Neurology LLP   (United States)

Author keywords

Dihydroergotamine; Headache; Intranasal; Pain; Refractory headache; Triptan

Indexed keywords

ALMOTRIPTAN; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NECK PAIN; NOSE CONGESTION; POSTTRAUMATIC HEADACHE; RETROSPECTIVE STUDY; SIDE EFFECT; TASTE AVERSION; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; DIHYDROERGOTAMINE; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 34247396950     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178883     Document Type: Article

References (20)

1. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
2. Lipton RB, Silberstein SD, Saper JR, et al. Why headache treatment fails. Neurology 2003;60:1064-70
3. Migranal [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals North America, 2006
4. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43: 144-66
5. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 1995;35:177-84
6. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285-91
7. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447-53
8. World Medical Association Policy. Declaration of Helsinki. Available from http://www.wma.net/e/policy/b3.htm [Last accessed 22 September 2006]
9. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156-62
10. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45
11. Jhee SS, Shiovitz T, Crawford AW, et al. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205
12. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004;101:4274-9
13. Orii R, Ohashi Y, Guo T, et al. Evidence for the involvement of spinal cord alpha1 adrenoceptors in nitrous oxide-induced antinociceptive effects in Fischer rats. Anesthesiology 2002;97: 1458-65
14. Kawasaki Y, Kumamoto E, Furue H, et al. Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology 2003;98:682-9
15. Willems EW, Valdivia LF, Villalon CM, et al. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 2003;23:245-57
16. Mansikka H, Erbs E, Borrelli E, et al. Influence of the dopamine D2 receptor knockout on pain-related behavior in the mouse. Brain Res 2005;1052:82-7
17. Lopez-Avila A, Coffeen U, Ortega-Legaspi JM, et al. Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulate cortex. Pain 2004;111:136-43
18. Stead M, Josephs KA. Successful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine. Headache 2005;45:378-80
19. Silberstein S, Young WB, Gebeline-Myers C, et al. DHE-45 for migraine with cutaneous allodynia (CA). In: Program Abstracts of the 47th Annual Scientific Meeting of the American Headache Society; June 23-26, 2005; Philadelphia, PA [abstract S92]
20. Pozo-Rosich P, Oshinsky M. Effects of dihydroergotamine (DHE) on central sensitization of neurons in the trigeminal nucleus caudalis. Program and abstracts of the American Academy of Neurology 57th Annual Meeting; April 9-16, 2005; Miami Beach, FL [abstract S19.003]